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Canaloplasty is a nonpenetrating blebless surgical technique for open-angle glaucoma, in which a flexible microcatheter is inserted
within Schlemm’s canal for the entire 360 degrees. When the microcatheter exits the opposite end, a 10-0 prolene suture is tied
and it is then withdrawn, by pulling microcatheter back through the canal in the opposite direction. Ligation of prolene suture
provides tension on the canal and facilitates aqueous outflow. The main advantage of canaloplasty is that this technique avoids the
major complications of fistulating surgery related to blebs and hypotony. Currently, canaloplasty is performed in glaucoma patients
with early to moderate disease and combination with cataract surgery is a suitable option in patients with clinically significant lens
opacities.
1. Introduction
Glaucoma is linked to substantial social and economic costs
due to its prevalence and deleterious impact on quality of
life. Although more than 66 million people worldwide are
estimated to be affected, up to 50% of glaucoma cases are
undiagnosed [1]. Several studies demonstrated that, low-
ering intraocular pressure (IOP), the principal risk factor
for glaucoma progression reduced the progression rate and
efficiently preserved sight [2–4]. Standard glaucoma treat-
ment is drug therapy followed by surgery when optimal
disease control is not obtained. Trabeculectomy, the gold
standard in glaucoma surgery, drains the aqueous humor
from the anterior chamber to the subconjunctival space
but is associated with a high rate of complications, that is,
hypotony, hyphema, choroidal detachment, suprachoroidal
hemorrhage, blebitis, and bleb-associated endophthalmitis
[5, 6]. Consequently, innovative surgical techniques, such
as viscocanalostomy and canaloplasty, were proposed to
control IOP. Canaloplasty may be considered the evolution
of viscocanalostomy which was described by Stegmann in
1985 [7]. As a nonperforating, blebless surgical technique,
canaloplasty was first performed by Lewis et al. in 2007 [8].
It aims at restoring natural aqueous outflow by means of
Schlemm’s canal dilation which is achieved by tensioning
with a 10.0 polypropylene suture. Canaloplasty has aroused
substantial interest among surgeons over the last few years.
2. Patient Selection
Correct patient selection is the key to canaloplasty success.
Canaloplasty is indicated for patients with mild-to-moderate
primary open-angle glaucoma and a low-to-mid-IOP target
[9]. Best indications are primary open-angle glaucoma, pseu-
doexfoliation glaucoma, and pigmentary glaucoma. Canalo-
plasty is also indicated for patients with advanced glaucoma
who are not candidates for trabeculectomy. It may be rec-
ommended for patients with thin conjunctiva who could be
at risk of bleb leaks and for individuals who cannot comply
with the posttrabeculectomy care schedule [10]. After failed
trabeculectomy, canaloplasty may be successful in patients
with an undamaged Schlemm’s canal. Counterindications
to canaloplasty are conditions with a trabecular meshwork
obstruction that prevents adequate cannulation of Schlemm’s
canal. These include chronic angle closure, narrow angles,
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Figure 1
angle recession, neovascular glaucoma, ocular hypertension
due to increased episcleral venous pressure and previous
surgery that precludes Schlemm’s canal cannulation such as
trabeculectomy, trabeculotomy, goniotomy, and argon laser
trabeculoplasty [11].
3. Surgical Procedure
Canaloplasty is an ab externo procedure. A 10-0 polypropy-
lene suture is positioned within Schlemm’s canal for 360∘
and then tensioned to dilate the canal and restore natural
aqueous outflow. Canaloplasty is usually performed in the
upper quadrants, with access through the upper-temporal or
upper-nasal quadrants. Some surgeons do, however, perform
surgery in the lower quadrant. Although a retrobulbar block
is commonly used, subconjunctival and topical anaesthesia
is sometimes preferred. The eye is infero-ducted by placing
a clear corneal traction suture near the limbus, and surgery
starts by dissecting the fornix-based conjunctival flap. Careful
conjunctiva and Tenon’s capsule dissection should be fol-
lowed by wet-field cautery. Antimetabolites are not used.
Then, a nonpenetrating double-flap dissection of the sclera
exposes Schlemm’s canal. First, a square-shaped, triangular,
or parabolic superficial scleral flap is created. Approximately
one-third to half-scleral thickness, it is 5mm wide and
5mm long. This flap must be dissected up to the clear
cornea about 1.5/2.0mm over the limbus. Second, a deep
scleral flap is dissected. A little smaller than superficial flap
(one-half to one millimeter), its dissection plane should
be immediately superficial to choroid. The deep scleral
flap is dissected until ciliary body/choroid becomes visible
(Figure 1) and Schlemm’s canal is opened and deroofed by
removing its inner wall (Figure 2). A paracentesis is then
performed to lower IOP and reduce the risk of perforating
the trabecular-Descemet membrane. The deep scleral flap is
removed. Schlemm’s canal openings are carefully dissected.
One opening is cannulated using a flexible microcatheter
(iTrack, iScience Interventional, Menlo Park, CA, USA)
(Figure 3) which is pushed forward through the entire
circumference of Schlemm’s canal until it exits the other
end. The microcatheter is 200 microns in diameter and its
tip is illuminated by a laser-diode microillumination system
(iLumin by iScience Interventional, Menlo Park, CA, USA)
which easily identifies the distal tip through the sclera as
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it advances in the canal. When the microcatheter exits the
opposite end, it is tied to a 10-0 polypropylene suture and
is then withdrawn, by pulling it back through the canal
in the opposite direction (Figure 4). During withdrawal,
a dedicated injector inserts a small amount of viscoelastic
material into Schlemm’s canal every two hours. When the
microcatheter encounters a stop the surgeon should not force
the viscoelastic material any further because Schlemm’s canal
rupture could cause collector channel blood to pool in the
Descemet detachment, increasing the risk of intracorneal
hematoma formation.
When the suture arrives at the original end, it is cut
from the microcatheter and the two ends are carefully
tightened to pull the trabecular meshwork inwards. Achiev-
ing correct suture tension is crucial for success. Adequate
contraction is needed for homogeneous stretching of the
entire circumference but excessive contraction could break
the inner wall (Figure 5). Correct suture positioning and
canal tension are checked intraoperatively by means of a
high-resolution ultrasound system (iUltrasound, iScience
Interventional, Menlo Park, CA, USA). After deep scleral flap
excision, the superficial scleral flap is closed tightly with 10-
0 vicryl (or nylon) sutures. Watertight closure is essential to
prevent bleb formation. The conjunctival flap is then sutured
with 10-0 vicryl sutures [9, 12].
One of the major difficulties in canaloplasty is the
tension suture placement and tightening. A flexible stent,
the Stageman Canal Expander (SCE) (Ophthalmos GmbH,
Schaffhausen, Switzerland) was developed to overcome this
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problem and tomake canaloplasty easier.This 9.0mmflexible
stent is made of polyamide and is designed to fill a quarter
of Schlemm’s canal circumference, thus maintaining dilation
and allowing the aqueous humor to access collector channels
through its fenestrations. Using a 6/0 carrier, stents are placed
in Schlemm’s canal after microcatheter dilatation. When the
microcatheter is withdrawn, stents are placed inside both
ends. Stents overcome the obstacle of angles over Schlemm’s
canal that the polypropylene prolene tip finds difficult to pass
over [12, 13].
4. Postoperative Treatment
Postoperatively, patients usually are treated with third or
fourth generation fluoroquinolone drops 4 times daily for
1 week and with steroid drops 4 times daily for 1-2 weeks.
Steroid therapy is generally tapered in the following 15–
30 days. Some authors also administer nonsteroid anti-
inflammatory drops in the first month of therapy [9].
5. Mechanism of Action
How canaloplasty lowers IOP is not fully understood but
enlargement of Schlemm’s canal and collector channels
probably plays a role. In fact, canaloplasty is less likely
to be successful in eyes with a nonreversible collapse of
collector channels or other outflow pathways that cannot be
mechanically enlarged. Since the effect of canaloplasty on IOP
appears to be correlated, at least in part, to suture tension,
some authors tried to measure the suture stent distension
of Schlemm’s canal inner wall. In a multicenter study using
high-resolution anterior segment ultrasound biomicroscopy
(UBM), Lewis et al. assessed the relationship between IOP
reduction and the degree of canal distension. A grading
system of suture tension on Schlemm’s canal was created
and eyes with a discernable postoperative distension were
identified (first group) and compared to eyes without (second
group). After two years, IOP was reduced by 31% in the
first group and by 20% in the second [14]. Using UBM and
anterior segment optical coherence tomography, Brandao et
al. [15] quantified Schlemm’s canal distension preoperatively
and at 12 and 36 months after surgery. Both methods were
equally efficient in identifying the suture/stent generated
inner wall which did not change significantly over time.
Moreover, when pre- and postoperative IOP differences were
large, there was a tendency towards a greater Schlemm’s canal
distension, suggesting the tensioning suture contributed to
IOP reduction. An adjunctive mechanism for IOP decrease
could be enhanced aqueous humor filtration across the sclera
and conjunctiva. Indeed, after successful canaloplasty, con-
focal laser-scanning microscopy demonstrated an increase
in conjunctival microcysts, which are a sign of enhanced
aqueous humor filtration across the sclera and conjunctiva
[16].
6. Results
Reports concurred that canaloplasty effectively achieved
good short- and long- term IOP reductions.
In 2007, Lewis et al. [8] published the results of a 1-
year international multicenter prospective study, showing
that canaloplasty reduced IOP by 36%. In 2009, the same
authors [14] presented a 2-year follow-up of patients after
canaloplasty, finding a 30% decrease in IOP (from 23.2 ±
4.0 to 16.3 ± 3.7mmHg). Need for medications also dropped
from 2.0 ± 0.8 to 0.6 ± 0.8. Grieshaber et al. [17] published
results of canaloplasty in 32 Caucasian subjects, observing
that, without medications, mean IOP fell from 27 ± 5.6 to
12.8 ± 1.5mmHg 12 months after surgery. Complete success
(IOP < 21mmHg without medications) was achieved in
93.8% of patients, IOP < 18mm Hg in 84.4% of cases, and
IOP < 16mmHg in 74.9%.
Grieshaber et al. [18] performed a long-term analysis in
2010 of canaloplasty outcomes in 60 black Africans with a
mean preoperative IOP of 45±12.1mmHg. At 3 years, with a
mean follow-up of 30.6 ± 8.4months, the mean IOP without
medications was 13.3 ± 1.7mmHg. Complete success (IOP
< 21mmHg without medications) was reached in 77.5% of
patients and partial success (IOP < 21mmHgwith or without
medications) in 81.6%. In 2011, Lewis et al. [19] reported the
results of a 3-year internationalmulticenter prospective study
on canaloplasty, as performed on 157 eyes with open-angle
glaucoma. Preoperatively, mean IOPwas 23.8±5mmHg and
number of medications was 1.8 ± 0.9. After three years, IOP
decreased to 15.2±3.5mmHgand the number ofmedications
fell to 0.8 ± 0.9, with 36.1% IOP reduction from baseline.
Complete success (IOP < 18mmHg without medications)
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was achieved in 36% of patients and partial success (IOP <
18mmHg with or without medications) in 77.5% [19].
In 2011, Bull et al. [20] analyzed the efficacy of canalo-
plasty in European patients with open-angle glaucoma,
reporting 3-year outcomes in a series of 93 eyes. Mean IOP
dropped from 23.0±4.3 to 15.1±3.1mmHg and the number
of medications fell from 1.9 ± 0.7 to 0.9 ± 0.9. In 2014,
Borisuth et al. [10] reported 3-year canaloplasty results in
214 eyes with open-angle glaucoma in patients who were
under maximum medical therapy before surgery. The mean
preoperative IOP of 29.4 ± 7.9mmHg decreased to 17.0 ±
4.2mmHg (42.2% mean IOP reduction). Complete success
(defined as a postoperative IOP ≤ 21mmHg, ≤18mmHg and
≤16mmHg without any medical treatment) was achieved
in 44.8%, 31.0%, and 24.1% of patients, respectively, while
partial success (defined as a postoperative IOP ≤ 21mmHg,
≤18mmHg, and ≤16mmHg with or without medical treat-
ment) was achieved in 86.2%, 58.6%, and 37.9% of patients,
respectively.
In 2015, Voykov et al. [21] reported a 5-year follow-up on
canaloplasty, observing the IOP reduction rate was similar
to the 3-year rate. At 1, 3, and 5 years, complete success
rates for IOP < 21mmHg were, respectively, 37%, 28%, and
10%, which are lower than the reported 40%–45% after three
years. The low 5-year complete success rate could be a sign of
canaloplasty losing efficacy over time. In this series, 65% of
eyes required further surgery for IOP control.
Comparative studies showed canaloplasty was more effi-
cacious in reducing IOP than viscocanalostomy [22] but less
so than trabeculectomy with mitomycin C [23–25]. In a 1-
year follow-up study, Ayyala et al. reported the mean IOP
reduction was 32% after canaloplasty and 43% after tra-
beculectomy with mitomycin C; furthermore, postoperative
need for medical therapy was 36% in the canaloplasty group
and 20% in the trabeculectomy group [23].
Bru¨ggemann et al. performed another comparative study
on 30 eyes in 15 patients. They had trabeculectomy with
mitomycin C in one eye (group 1) and canaloplasty in the
other (group 2). After 1 year, mean IOP decreased from 26.3±
10.9 to 11.6 ± 5.2mmHg in group 1 and from 26.8 ± 6.4
to 13.2 ± 2.8mmHg in group 2. The number of glaucoma
medications fell from 2.7 to 0.4 ± 0.7 in group 1 and from 2.5
to no medication in group 2. Moreover, the trabeculectomy
group required a longer postoperative hospital stay (10.4±2.8
versus 5.4±1.0 days) as well as more postoperative check-ups
(8.5 ± 3.6 versus 3.9 ± 0.8) and interventions [24].
In 2014, in a retrospective study, Thederan et al. [26]
compared outcomes in 22 eyes after trabeculectomy and in
22 eyes after canaloplasty. Mean IOP in the trabeculectomy
and canaloplasty groups decreased from 23.9 ± 10.7 to 10.8
± 3.7mmHg and from 23.7 ± 7.6 to 14.5 ± 3.8mmHg,
respectively. Complete success (defined as IOP < 21mmHg
and 20% IOP reduction from baseline without medication),
was achieved in 18 eyes (81.8%) after trabeculectomy and in 11
eyes (50.0%) after canaloplasty [26]. In a prospective, 2-year
follow-up randomized clinical trial, Matlach et al. compared
outcomes of canaloplasty and trabeculectomy in open-angle
glaucoma. They observed that both approaches significantly
reduced IOP. The mean absolute IOP reduction was 10.8
± 6.9mmHg after trabeculectomy and 9.3 ± 5.7mmHg after
canaloplasty while the mean IOP was 11.5 ± 3.4mmHg after
trabeculectomy and 14.4 ± 4.2mmHg after canaloplasty.
Complete success (IOP ≤ 18mmHg without medication)
was achieved in, respectively, 74.2% and 39.1%, while partial
success (IOP ≤ 18mmHg with or without medication) was
achieved in 67.7% after trabeculectomy and in 39.1% after
canaloplasty. Following trabeculectomy, complications were
more frequent and included hypotony (37.5%), choroidal
detachment (12.5%) and elevated IOP (25.0%) [25].
In 2014, Klink and coworkers [27] assessed quality of
life and patient satisfaction after canaloplasty and trabeculec-
tomy. Patients reported a better quality of life after canalo-
plasty, particularly with regard to positive postoperative
mood, satisfaction with outcome, and lower rates of visual
and nonvisual symptoms. In the trabeculectomy group, the
authors registered higher stress rates due to surgery, postsur-
gical treatments, and check-ups and a lower satisfaction rate.
They reported that 41% of patients were highly satisfied after
trabeculectomy and 57% after canaloplasty. No intergroup
differences emerged in restriction from social contacts and
loss of independence.
7. Combined Surgery
Combining canaloplasty and phacoemulsification surgery is a
suitable option in patients with clinically significant cataract.
Cataract surgery alone is known to reduce IOP but the effect
is generally small, probably because the wider angle and
trabecular meshwork tensioning increased aqueous humor
outflow [28]. The combined approach provided a greater
hypotensive effect than canaloplasty alone [19, 29]. Angle
architecture modification probably resulted in a more open
configuration and in trabecular meshwork tensioning which
increased aqueous humor outflow [28, 29].
In 2009, Lewis et al. [14] presented a 2-year follow-up of
patients after phacocanaloplasty, finding a 42% decrease in
IOP. IOP dropped from 23.1± 5.5 to 13.4± 4.0mmHg and the
number of medications fell from 1.7 ± 1.0 to 0.2 ± 0.4. In a 3-
year study after phacocanaloplasty, Lewis et al. found a 42.1%
reduction in IOP from baseline. The mean IOP decreased
from 23.5 ± 5.2mmHg with 1.5 ± 1.0 medications to 13.6 ±
3.6mmHg with 0.3 ± 0.5 medications. Use of hypotensive
medications was reduced in 80% of patients [19]. In 2011, Bull
et al. analyzed the efficacy of phacocanaloplasty in 16 eyes.
The mean preoperative IOP fell from 24.3 ± 6.0mmHg with
1.5 ± 1.2 medications to 13.8 ± 3.2mmHg with 0.5 ± 0.7
medications after 3 years [20].
Similar results were found by Matlach et al. [30] 12
months after surgery. Phacotrabeculectomy lowered IOP
more than phacocanaloplasty, but the difference was not sig-
nificant. Moreover, the phacotrabeculectomy group needed
fewer glaucoma medications (0.2 ± 0.4) than the phaco-
canaloplasty group (1.0 ± 1.5). In 2015, Schoenberg et al. [31]
observed that phacocanaloplasty and phacotrabeculectomy
resulted in comparable mean IOP at 12 months and they
reported significant reduction in IOP and improvement in
visual acuity with comparable success rates.
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In 2015, in a comparative, prospective, randomized study,
Rękas et al. [32] reported 1-year outcomes after phaco-
canaloplasty and phaco-nonpenetrating deep sclerectomy.
Both techniques effectively reduced IOP with similar effi-
cacy and safety profiles. Patients who underwent phaco-
nonpenetrating deep sclerectomy required additional proce-
dures like 5-FU injections, suture lysis, or needling, while
phacocanaloplasty patients required no additional proce-
dures.
8. Adverse Events
Although the rate of complications, particularly severe com-
plications, is lower after canaloplasty than trabeculectomy
[23], surgeons need to be aware of potential pitfalls that can
occur during and after canaloplasty. Inability to cannulate
Schlemm’s canal is a major intraoperative complication as
cannulation is successful in only 74–89.9% of cases [9,
19, 20, 29]. Failures may be due to anatomical anomalies
of Schlemm’s canal, to trabecular meshwork scars due to
previous argon laser trabeculoplasty, or to surgical inexperi-
ence [19, 29]. When cannulation fails, the operation can be
converted to deep sclerectomy or to viscocanalostomy [9].
Microcatheter escape from Schlemm’s canal into sur-
rounding structures is a rare complication. Grieshaber et al.
reported catheter penetration of the anterior chamber in one
case and of the suprachoroidal space in another [18]. These
two cases accounted for 3.3% of all complications in the
Grieshaber study.
Descemet’s membrane detachment in 1.6–9.1% of cases is
another rare intraoperative complication [9, 17, 19, 20, 29]. It
may occur if, upon encountering a difficulty in cannulation,
attempts to force injection of viscoelastic material lead to
channel rupture [9]. Descemet’s membrane detachments are
usually limited in size (1-2mm) and resolve spontaneously,
but sometime they may reach the visual axis and require
surgery [33].
Postoperative complications are divided into early (1–
10 days after surgery) and late (2–5 weeks after surgery).
The most common early postoperative complication, which
is observed in 6.1% to 85.2% of cases, is bleeding from
Schlemm’s canal into the anterior chamber on the first day
after surgery [9, 19, 20, 34]. Blood reaching the anterior
chamber from the collector channels is considered a pos-
itive prognostic factor because it may indicate the outflow
pathways are open and functioning [34]. Hyphema is usually
transient, resolving spontaneously andwithout consequences
in up to one month [17, 19, 20].
A transient increase in IOP that can reach 30mmHg
or more is another early postoperative complication that
was reported in 1.6–18.2% of eyes. It is probably due to
residual viscoelasticmaterial in Schlemm’s canal that prevents
aqueous humor from passing into the collector channels.
IOP usually stabilizes after 24–48 hours when all residual
viscoelastic is reabsorbed [9] and the increase rarely persists
for 3-4 weeks. Should it do so, laser goniopuncture might be
efficient.
Hypotony, a rare, transient complication (0.6%–9.8%) [9,
19, 20], is due to superficial flap sutures not being watertight.
Late complications of canaloplasty include cataract for-
mation in 12.7% to 19.1% of patients according to diverse
studies [19, 20] and long-term failure which may be treated
with laser goniopuncture to reduce IOP and, if that fails,
trabeculectomy.
Bleb formation is rare (2.5%) especially after phaco-
canaloplasty [19, 35].
9. Conclusions
Canaloplasty appears to be a valid alternative to conventional
glaucoma surgery because of its efficacy and safety profile
in selected patients with open-angle glaucoma. Its advan-
tages over trabeculectomy include absence of subconjunctival
bleb, no need for mitomycin C, faster visual rehabilitation,
easier follow-up, and fewer postoperative complications. On
the other hand, disadvantages are the long learning curve,
need for specifically designed instruments, impossibility to
perform the surgery properly in some cases, and a lower IOP
reduction compared with trabeculectomy.
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